about
Lipid peroxidation: pathophysiological and pharmacological implications in the eyeThe endocannabinoid system as an emerging target of pharmacotherapyEndocannabinoids in the retina: from marijuana to neuroprotectionThe Endocannabinoid System as a Therapeutic Target in GlaucomaEndogenous and Synthetic Cannabinoids as Therapeutics in Retinal DiseaseMarijuana for Glaucoma: A Recipe for Disaster or Treatment?Turning Down the Thermostat: Modulating the Endocannabinoid System in Ocular Inflammation and PainFocus on cannabinoids and synthetic cannabinoids.C-ring cannabinoid lactones: a novel cannabinergic chemotype.Metabolic syndrome as a risk factor for elevated intraocular pressure.Probing the carboxyester side chain in controlled deactivation (-)-δ(8)-tetrahydrocannabinols.Enhanced solubility, stability, and transcorneal permeability of δ-8-tetrahydrocannabinol in the presence of cyclodextrins.Cannabinoids and glaucomaOcular associations of metabolic syndromeCannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?Heat shock protein 90 is an essential molecular chaperone for CB2 cannabinoid receptor-mediated signaling in trabecular meshwork cells.The cannabinoid system and its pharmacological manipulation--a review, with emphasis upon the uptake and hydrolysis of anandamide.Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization, and in vitro evaluation.Fixed-combination and emerging glaucoma therapies.Cannabis and endocannabinoid modulators: Therapeutic promises and challenges.Heteroadamantyl cannabinoids.Topical WIN55212-2 alleviates intraocular hypertension in rats through a CB1 receptor mediated mechanism of actionInvolvement of a non-CB1/CB2 cannabinoid receptor in the aqueous humor outflow-enhancing effects of abnormal-cannabidiol.Controlled-deactivation cannabinergic ligands.Biochemical changes and treatment in glaucoma.Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes.Neuroprotection by (endo)cannabinoids in glaucoma and retinal neurodegenerative diseases.Phytochemistry of Cannabis sativa L.In-vitro corneal permeation of cannabinoids and their water-soluble phosphate ester prodrugs.Endocannabinoids alleviate proinflammatory conditions by modulating innate immune response in muller glia during inflammation.
P2860
Q21129236-7F5FBFFE-0272-4CC5-8238-07B580D2EFBCQ24648473-BB6E1AEF-04CE-4A90-B11A-1890B653DBD9Q24656049-24532616-1942-4082-86AC-5C22617E1DA3Q26765508-DDBE3D29-5F15-434C-A6F3-77485B9768AAQ26765576-D905C1B4-F070-4A41-8014-E081394FDAA5Q26785465-11467EAD-8956-45E8-9BB7-AE1846B9150EQ28066928-A3B5C381-7463-407B-A29A-7EED2117F4C3Q30241053-A6A41A25-CBFB-4CEC-9B43-AAA6F7565FE6Q33636166-6BE64BEF-A650-4C2B-BFDB-B7BCA1A80C36Q33722498-5883FF3A-8299-46D9-99A3-FCA34FB0C53CQ35013538-5072017C-AB21-4804-BD6F-59F9100551B3Q35100405-A81878C9-3825-4022-927F-B951506DC4F0Q35748271-391D40C3-65D6-42A5-ADB6-56EE474BC59FQ35968037-BC376067-CA47-4C8B-9486-35564EB3FDDBQ36157657-85098667-4F42-4060-BF6F-BD86C7ADB7F1Q36458935-5E7ADD66-7D62-4D19-9E48-6B600019466EQ36655240-45797A97-447E-4B46-BB69-3FC2F176CBBEQ36697414-F9AB1E09-DB67-4027-9729-209818E6FBAAQ36866626-48BA220B-B8DF-40BE-B5AB-2CEEB31738A4Q36892931-10887F6A-93C3-4431-8821-3B7F67C10AD9Q36975503-4AADFF40-4292-4846-A658-AF9E1F1EF987Q37086961-616CC7C9-8F28-4AE8-9BEF-B4DE8AC2EF11Q37361093-18929FFB-64B5-477E-B6FF-CB52597A2C9EQ37527191-8590CE00-85C3-40CE-B1BC-9F1136078A7FQ38443580-FBFA9ABE-3813-4FC4-8A65-70018ACD646EQ38598509-FC88AD57-7923-4AA2-8A2B-55F0218A8A81Q38664371-2930DE4F-4830-4E64-B9A1-52A35954E4FBQ39102178-0EA20925-3852-4F00-8BE7-BA0DD4624CA8Q46654403-36FD000C-F3CB-4B85-8856-BBCA209EA110Q53102889-1019D0F6-BA8E-4FA7-B246-1DD47AE1549D
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Cannabinoids in the treatment of glaucoma.
@ast
Cannabinoids in the treatment of glaucoma.
@en
Cannabinoids in the treatment of glaucoma.
@nl
type
label
Cannabinoids in the treatment of glaucoma.
@ast
Cannabinoids in the treatment of glaucoma.
@en
Cannabinoids in the treatment of glaucoma.
@nl
prefLabel
Cannabinoids in the treatment of glaucoma.
@ast
Cannabinoids in the treatment of glaucoma.
@en
Cannabinoids in the treatment of glaucoma.
@nl
P2093
P1476
Cannabinoids in the treatment of glaucoma.
@en
P2093
David W Pate
Krista Laine
Tomi Järvinen
P304
P356
10.1016/S0163-7258(02)00259-0
P577
2002-08-01T00:00:00Z